Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06480201 · ClinicalTrials.gov registry record · Phase 1
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
A Phase 1 study, sponsored by Texas A&M University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT06480201 is a Phase 1 study that is actively recruiting participants, run by Texas A&M University. The registered enrollment target is 100 participants.
The verdict
NCT06480201, a Phase 1 study, is actively recruiting participants, sponsored by Texas A&M University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion. Our study design captures the clinical variation associated with real-world treatment resistant depression (TRD) patients and allows us to analyze the relative importance of GBP to antidepressant symptom reduction across the induction phase of treatment. If successful, it provides a compelling rationale for a larger prospective investigation of gamma dynamics as a moderator of outcome to varied TRD therapies which impact the balance of cortical excitation and inhibition.
Interventions
- DRUG Ketamine
- OTHER Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06480201
The ClinicalTrials.gov registry entry for NCT06480201 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas A&M University, which has 95 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT06480201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06480201 about?
NCT06480201 is a clinical study titled "Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression". The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (...
What is the current status of trial NCT06480201?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-01-01. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT06480201?
The interventions under investigation include: Ketamine (DRUG), Saline (OTHER).
Who is sponsoring clinical trial NCT06480201?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.